Tarsus Acquisition Target Alkeus Announces JAMA Ophthalmology Publication Of TEASE-1 Data Showing Gildeuretinol Cut Retinal Lesion Growth Rate 21.6% vs. Untreated In 50-Patient Stargardt Disease Trial
Share
Why It Matters
Alkeus, a company Tarsus wants to buy, tested a new eye medicine on 50 patients with a disease that hurts vision. The medicine slowed down eye damage by about 22% compared to doing nothing, and doctors published these results in a major medical journal.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.